Global Inflammatory Bowel Disease Market Companies
- Abbvie, Inc.a
- Janssen Biotech Inc.
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novartis AG.
- Biogen Idec, Inc.
- Cosmo Pharmaceuticals SpA
- ChemoCentryx, Inc.
- Falk Pharma GmbH
- Eisai Co, Ltd.
Recent News:
- The once-daily oral drug VELSIPITYTM (etrasimod), a selective sphingosine-1-phosphate (S1P) receptor modulator, was approved by the U.S. Food and Drug Administration (FDA) in October 2023 for use in treating patients with moderately to severely active ulcerative colitis (UC). For VELSIPITY, a recommended dose of 2 mg has been approved. A once-daily oral medication with an excellent benefit-risk profile called VELSIPITY may help people with moderately to highly active UC achieve steroid-free remission.
- Teva Pharmaceuticals, an American division of Teva Pharmaceutical Industries Ltd., and Sanofi announced in October 2023 that they would collaborate to co-develop and co-commercialize TEV'574, a treatment for inflammatory bowel disease currently undergoing Phase 2b clinical trials for ulcerative colitis and Crohn’s disease. According to the conditions, In addition to an upfront payment of €469 million ($500 million) under the new cooperation agreement, Teva will receive milestone payments for development and launch of up to €940 million ($1 billion).
- With the FDA's October 2023 approval of lebrikizumab, a promising induction and maintenance therapy for ulcerative colitis, patients with this severe and chronic inflammatory bowel disease will have a new treatment option. This therapy offers a safe and effective therapeutic alternative for patients with moderate-to-severely active UC who have not yet demonstrated rapid and significant improvements with currently available medications. Mirikizumab, in contrast to other UC drugs, also relieves bowel urgency, a significant symptom that significantly lowers patients' quality of life.